The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | John Gribben’s ASH 2019 CLL and lymphoma highlights
John Gribben, MD, DSc, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, gives a round up of lymphoma and chronic lymphocytic leukemia (CLL) research that has been presented at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL, including longer follow-up and novel agents in early development. While majority of the updates may not be changing the therapeutic landscape completely, they none-the-less are crucial for optimizing treatment.
